News

Read our latest news, and find more about us and our portfolio companies.

2017/09/16
Why M Ventures is Investing in Synthetic Biology Companies – Meet Andreas Jurgeit

This week we interviewed someone who is passionate about startups that are transforming innovative ideas into commercial success with real-world benefits, as well as new ideas around life science technologies. Andreas Jurgeit, Investment Director of the Life Science team at M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (for simplicity called M Ventures in the US and Canada), will be speaking in the Synthetic Biology Investor Panel (sponsored by Alexandria Real Estate Equities) at SynBioBeta SF 2017 on October 4th.

2017/08/23
Merck Sets Up PMatX Incubator in Israel for Next-Generation Electronics

- Focused on start-up companies dealing with next-generation electronics that integrate advanced materials with novel manufacturing methods - Industrial partners include HP - Located in Israel; overall investment volume of around € 20 million; initial commitment for 3 years

2017/06/22
Digital Health

Die Digitalisierung macht vor keinem Bereich halt – so betrifft sie auch zunehmend das Geschäft mit der Gesundheit. Start-ups mischen traditionelle Geschäftsfelder auf – ihr Vorstoß wirft viele neue Fragen auf.